regn1979
mAbexperimentalMulti-specific
Clinical trial activity
16 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
9
Phase 3
6
Phase 4
0
Earliest trial started Nov 1, 2014 (NCT02290951)
Timeline
Indications
Studied for
Mechanism of action
- T cell surface glycoprotein CD3BINDING AGENT
T cell surface glycoprotein CD3 binding agent
Bispecific antibody that also engages T-cells through CD3.
- B-lymphocyte antigen CD20BINDING AGENT
B-lymphocyte antigen CD20 binding agent
Bispecific antibody that also engages T-cells through CD3.
- B-lymphocyte antigen CD20INHIBITOR
MS4A1 inhibitor
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298084 ↗
Also known as
- regn1979
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06975787 | Phase 1 | Nov 6, 2025 | Regeneron |
| NCT07128641 | Phase 2 | Oct 31, 2025 | Harvard University, Regeneron |
| NCT06735664 | Phase 1 | Aug 14, 2025 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT06784726 | Phase 2 | Apr 1, 2025 | Regeneron, University of Washington |
| NCT06854159 | Phase 2 | Apr 1, 2025 | National Cancer Institute (NCI), University of California, Davis |
| NCT06230224 | Phase 3 | Feb 15, 2024 | Regeneron |
| NCT06149286 | Phase 3 | Dec 18, 2023 | Regeneron |
| NCT06091254 | Phase 3 | Dec 12, 2023 | Regeneron |
| NCT06091865 | Phase 3 | Dec 11, 2023 | Regeneron |
| NCT06097364 | Phase 3 | Nov 14, 2023 | Regeneron |
| NCT05991388 | Phase 2/Phase 3 (Phase 3) | Oct 31, 2023 | ADC Therapeutics SARL, Cancer Research UK, Fight Kids Cancer, Regeneron, University of Birmingham, University of Cambridge |
| NCT05685173 | Phase 1 | Apr 12, 2023 | Regeneron |
| NCT03888105 | Phase 2 | Jun 21, 2019 | Regeneron |
| NCT02651662 | Phase 1 | Nov 1, 2015 | Regeneron |
| NCT02290951 | Phase 1 | Nov 1, 2014 | Regeneron |
| NCT05619367 | N/A | — | Regeneron |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Regeneron | For profit | 14 | 11 | 4 | 2014 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2025 |
| ADC Therapeutics SARL | For profit | 1 | 0 | 1 | 2023 |
| Cancer Research UK | Academic/Hospital | 1 | 0 | 1 | 2023 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Fight Kids Cancer | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Birmingham | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of California, Davis | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Cambridge | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2025 |
11 organizations
Page 1 / 1